Screener
Iovance Biotherapeutics, Inc. IOVA Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Interest and other income, net | 3,217 | 4,104 | 4,550 | 7,324 |
| Net Loss before income taxes | $(48,688) | $(109,670) | $(128,398) | $(227,671) |
| Income tax benefit (expense) | 1,373 | (1,988) | 2,038 | (150) |
| Net Loss | $(47,315) | $(111,658) | $(126,360) | $(227,821) |
| Net Loss Per Share of Common Stock, Basic and Diluted | $(0.11) | $(0.33) | $(0.29) | $(0.69) |
| Weighted Average Shares of Common Stock Outstanding, Basic and Diluted | 450,189 | 334,511 | 434,437 | 328,721 |
| * Non-cash stock-based compensation included in cost of sales and operating expenses | ||||
| Cost of sales | $1,536 | $2,149 | $2,555 | $4,569 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s business segments — net income loss?
- Iovance Biotherapeutics, Inc. (IOVA) reported business segments — net income loss of -$47.32M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s business segments — net income loss changed year-over-year?
- Iovance Biotherapeutics, Inc.'s business segments — net income loss increased by 57.6% year-over-year, from -$111.66M to -$47.32M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s business segments — net income loss?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s business segments — net income loss has grown at a -6.2% compound annual growth rate (CAGR), from -$444.04M to -$390.98M.
- What does business segments — net income loss mean?
- Indicates the bottom-line financial performance of the business segment after accounting for all revenues and operating expenses. For a clinical-stage biopharmaceutical company, this metric highlights the segment's current profitability status and the extent of capital burn required to advance its therapeutic pipeline.
Ask your AI about Iovance Biotherapeutics, Inc.'s business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude